Taheri, A.; Almasri, R.; Wignall, A.; Feltrin, F.; Bremmell, K.E.; Joyce, P.; Prestidge, C.A.
Enteric Coating Enhances the Biopharmaceutical Performance of a Silica–Lipid Formulation of Abiraterone Acetate. Pharmaceutics 2025, 17, 1289.
https://doi.org/10.3390/pharmaceutics17101289
AMA Style
Taheri A, Almasri R, Wignall A, Feltrin F, Bremmell KE, Joyce P, Prestidge CA.
Enteric Coating Enhances the Biopharmaceutical Performance of a Silica–Lipid Formulation of Abiraterone Acetate. Pharmaceutics. 2025; 17(10):1289.
https://doi.org/10.3390/pharmaceutics17101289
Chicago/Turabian Style
Taheri, Ali, Ruba Almasri, Anthony Wignall, Felicia Feltrin, Kristen E. Bremmell, Paul Joyce, and Clive A. Prestidge.
2025. "Enteric Coating Enhances the Biopharmaceutical Performance of a Silica–Lipid Formulation of Abiraterone Acetate" Pharmaceutics 17, no. 10: 1289.
https://doi.org/10.3390/pharmaceutics17101289
APA Style
Taheri, A., Almasri, R., Wignall, A., Feltrin, F., Bremmell, K. E., Joyce, P., & Prestidge, C. A.
(2025). Enteric Coating Enhances the Biopharmaceutical Performance of a Silica–Lipid Formulation of Abiraterone Acetate. Pharmaceutics, 17(10), 1289.
https://doi.org/10.3390/pharmaceutics17101289
